BACKGROUND: Patients are participating more actively in health care decision-making with regard to their health, as well as in the broader realm of assessing the value of medical products and influencing decisions about their registration and reimbursement. There is an increasing trend to include patients' perspectives throughout the stages of medical product development by broadening the traditional study-participant role to that of an active partner throughout the process. Including patients in the selection and development of clinical outcome assessments (COAs) to evaluate the benefit of treatment is particularly important. Still, despite widespread enthusiasm, there is substantial uncertainty regarding how and when to engage patients in this process. PURPOSE: This manuscript proposes a methodological framework for engaging patients at varying levels in the selection and development of COAs for medical product development. FRAMEWORK: The framework builds on the Food and Drug Administration's roadmap for patient-focused COA. Methods for engaging patients across each stage in this roadmap are summarized by levels of engagement. Opportunities and examples of patient engagement (PE) in the selection and/or development of COAs are summarized, together with best practices and practical considerations. CONCLUSION: This paper offers a framework for understanding, planning, and implementing methods to advance PE in the selection and/or development of COAs for evaluating the benefit of medical products. The intent is to further this important discussion and enhance the process and outcome of PE in this context.
BACKGROUND:Patients are participating more actively in health care decision-making with regard to their health, as well as in the broader realm of assessing the value of medical products and influencing decisions about their registration and reimbursement. There is an increasing trend to include patients' perspectives throughout the stages of medical product development by broadening the traditional study-participant role to that of an active partner throughout the process. Including patients in the selection and development of clinical outcome assessments (COAs) to evaluate the benefit of treatment is particularly important. Still, despite widespread enthusiasm, there is substantial uncertainty regarding how and when to engage patients in this process. PURPOSE: This manuscript proposes a methodological framework for engaging patients at varying levels in the selection and development of COAs for medical product development. FRAMEWORK: The framework builds on the Food and Drug Administration's roadmap for patient-focused COA. Methods for engaging patients across each stage in this roadmap are summarized by levels of engagement. Opportunities and examples of patient engagement (PE) in the selection and/or development of COAs are summarized, together with best practices and practical considerations. CONCLUSION: This paper offers a framework for understanding, planning, and implementing methods to advance PE in the selection and/or development of COAs for evaluating the benefit of medical products. The intent is to further this important discussion and enhance the process and outcome of PE in this context.
Entities:
Keywords:
Clinical outcome assessment; Drug development; Medical product development; Patient centered; Patient engagement; Patient focused
Authors: Thomas W Concannon; Paul Meissner; Jo Anne Grunbaum; Newell McElwee; Jeanne-Marie Guise; John Santa; Patrick H Conway; Denise Daudelin; Elaine H Morrato; Laurel K Leslie Journal: J Gen Intern Med Date: 2012-04-13 Impact factor: 5.128
Authors: Kelly P McCarrier; Scott Bull; Sarah Fleming; Kristina Simacek; Paul Wicks; David Cella; Renee Pierson Journal: Value Health Date: 2015-12-11 Impact factor: 5.725
Authors: Asha Hareendran; Juliana Setyawan; Robin Pokrzywinski; Anna Steenrod; Manisha Madhoo; M Haim Erder Journal: Health Qual Life Outcomes Date: 2015-08-22 Impact factor: 3.186
Authors: Lori Frank; Laura Forsythe; Lauren Ellis; Suzanne Schrandt; Sue Sheridan; Jason Gerson; Kristen Konopka; Sarah Daugherty Journal: Qual Life Res Date: 2015-01-06 Impact factor: 4.147
Authors: Juan Pablo Domecq; Gabriela Prutsky; Tarig Elraiyah; Zhen Wang; Mohammed Nabhan; Nathan Shippee; Juan Pablo Brito; Kasey Boehmer; Rim Hasan; Belal Firwana; Patricia Erwin; David Eton; Jeff Sloan; Victor Montori; Noor Asi; Abd Moain Abu Dabrh; Mohammad Hassan Murad Journal: BMC Health Serv Res Date: 2014-02-26 Impact factor: 2.655
Authors: Marc Boutin; Lode Dewulf; Anton Hoos; Jan Geissler; Veronica Todaro; Roslyn F Schneider; Vincenzo Garzya; Andrew Garvey; Paul Robinson; Tonya Saffer; Sarah Krug; Ify Sargeant Journal: Ther Innov Regul Sci Date: 2016-08-20 Impact factor: 1.778
Authors: Peter A Merkel; Michele Manion; Rashmi Gopal-Srivastava; Stephen Groft; H A Jinnah; David Robertson; Jeffrey P Krischer Journal: Orphanet J Rare Dis Date: 2016-05-18 Impact factor: 4.123
Authors: Heather L Gelhorn; Matthew H Kulke; Thomas O'Dorisio; Qi M Yang; Jessica Jackson; Shanna Jackson; Kristi A Boehm; Linda Law; Jacqueline Kostelec; Priscilla Auguste; Pablo Lapuerta Journal: Clin Ther Date: 2016-03-31 Impact factor: 3.393
Authors: Trisha Greenhalgh; Lisa Hinton; Teresa Finlay; Alastair Macfarlane; Nick Fahy; Ben Clyde; Alan Chant Journal: Health Expect Date: 2019-04-22 Impact factor: 3.377